Extra chemotherapy if tumor DNA stays positive after osimertinib
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This Phase 2 trial tests whether adding chemotherapy can help people with EGFR-mutated lung cancer when their cancer-related blood test (liquid biopsy for EGFR DNA) is still positive after 3–4 weeks of starting osimertinib. It may help slow the cancer for longer by treating any remaining disease activity.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older and have stage IIIB or IV non-small cell lung cancer (NSCLC)
- Your tumor must have an EGFR mutation called Ex19del or L858R
- You must start osimertinib 80 mg once daily as your first treatment (or have started it within the last 28 days)
- You must have recent CT or MRI scans of your chest and abdomen within the last 42 days
- You must have a persistent positive EGFR blood test (liquid biopsy) 21–28 days after starting osimertinib
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether adding an extra targeted medicine (anlotinib) to standard chemotherapy (pemetrexed and carboplatin) can better control osimertinib-resistant lung cancer with an EGFR mutation. It’s for people whose lung cancer has already progressed after osimertinib, and it aims to shrink tumors and slow the disease.
This trial tests whether adding chemotherapy to the standard targeted therapy osimertinib can improve outcomes for people with a specific type of advanced lung cancer that has not responded fully to osimertinib alone. It is for those whose cancer has a particular EGFR mutation and who still have detectable cancer DNA in their blood after starting osimertinib.
This trial tests a new combination of the drug osimertinib with chemotherapy for people whose lung cancer has returned after they took osimertinib alone following surgery. It aims to see if this combined approach helps control the cancer better.
This trial tests a personalized treatment plan for advanced lung cancer with an EGFR mutation. It uses a blood test (ctDNA) to guide treatment with osimertinib (a targeted pill) plus chemotherapy. The goal is to see if adjusting therapy based on the blood test results can help you live longer with fewer side effects.
This trial tests whether osimertinib alone is as good as osimertinib plus chemotherapy for lung cancers that have a specific EGFR mutation. It may help by improving how well the cancer responds and slows growth in people with metastatic non-small cell lung cancer.
This Phase 2 study tests a treatment sequence starting with osimertinib, then using chemotherapy after it. It is meant for people with EGFR-mutated advanced lung cancer whose disease has come back or progressed, including a “rechallenge” attempt with osimertinib.
Hear when a new NSCLC Stage IV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.